Challenges with drug combinations
Highlights of ASH in CLL
John Gribben et al.
Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AML
Achieving deep responses in previously treated CLL patients
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?